Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage

Summary

The CASH study is a randomized, double-blind, placebo-controlled trial evaluating whether adding cilostazol to standard nimodipine therapy improves neurological outcomes in patients with aneurysmal subarachnoid hemorrhage (aSAH). The primary objective is to assess functional outcome at 6 months using the modified Rankin Scale. A total of 630 patients will be enrolled within 96 hours of aSAH onset and treated for 14 days. The study is conducted across 9 centers in France, funded by a PHRC, and overseen by an independent monitoring board.

Timeline

Start

2025-12-15

Primary completion

2029-12-14

Completion

2029-12-14

Drugs

Indications